U.S. markets closed

Metacrine, Inc. (MTCR)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
8.03+0.03 (+0.37%)
At close: 4:00PM EST

Metacrine, Inc.

3985 Sorrento Valley Boulevard
Suite C
San Diego, CA 92121
United States

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Ms. Trisha M. MillicanChief Financial Officer381.47kN/A1973
Dr. Hubert C. ChenChief Medical Officer440.14kN/A1969
Dr. Preston S. KlassenPres, CEO & DirectorN/AN/A1969
Ms. Patricia MillicanChief Financial OfficerN/AN/A1973
Ms. Catherine C. LeeSr. VP & Gen. CounselN/AN/A1974
Ms. Theresa LowryVP of HRN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with liver and gastrointestinal diseases in the United States. It is developing MET409, a therapy that is in a Phase Ib proof-of-concept clinical trial for the treatment of non-alcoholic steatohepatitis patients; and MET642, a candidate, which is in Phase 1 clinical trial for the treatment of non-alcoholic steatohepatitis patients. The company has a research collaboration with Novo Nordisk A/S to perform research activities related to fibroblast growth factor 1. Metacrine, Inc. was founded in 2014 and is headquartered in San Diego, California.

Corporate Governance

Metacrine, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.